Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 16.07
Day High 16.59
Open:16.33
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals -- New Research Emphasizes Economic Growth
GlobeNewswire - Thu Dec 27, 6:24AM CST
GlobeNewswire - CMTX
Thu Dec 27, 6:24AM CST
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Capricor Therapeutics, Inc. (NASDAQ:CAPR), Appian Corporation (NASDAQ:APPN), Yext Inc. (NYSE:YEXT), Agile Therapeutics, Inc. (NASDAQ:AGRX), and Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
PR Newswire - Wed Dec 26, 7:00AM CST
PR Newswire - CMTX
Wed Dec 26, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 10:30 a.m. PT / 1:30 p.m. ET. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)
ACCESSWIRE - Tue Dec 4, 9:51AM CST
ACCESSWIRE - CMTX
Tue Dec 4, 9:51AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2018 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: .
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 13.24 +24.09% increase
on 12/24/18
Period Open:14.46
Price movement based on the high, low and last over the given period.
16.59 -0.96% decrease
on 01/18/19
+1.97 (+13.62%) increase
since 12/18/18
3-Month 13.24 +24.09% increase
on 12/24/18
Period Open:17.59
Price movement based on the high, low and last over the given period.
17.38 -5.47% decrease
on 10/19/18
-1.16 (-6.59%) decrease
since 10/18/18
52-Week 13.24 +24.09% increase
on 12/24/18
Period Open:17.85
Price movement based on the high, low and last over the given period.
21.48 -23.51% decrease
on 03/20/18
-1.42 (-7.96%) decrease
since 01/18/18

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement